Lv7
4490 积分 2021-09-04 加入
工作太多了！
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
4天前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
4天前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
4天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
14天前
已完结
Tumor-associated macrophages: Potential therapeutic targets and diagnostic markers in cancer
3个月前
已完结
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
4个月前
已完结
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
4个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
4个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
5个月前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
5个月前
已完结
皖公网安备34019202002308
